Evidence map›Paper›PMID 40731114›Full record

ArticleScientific reports2025

The value of acetylation reader YEATS2 in hepatocellular carcinoma management.

Yongjie Shi, Qiwen Xiao, Weichun Xiao, Jiale Kang, Qiang Zhou, Hongyun Jia, Yimei Chen, Sicong Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yongjie Shi *Department of Clinical Laboratory, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Qiwen Xiao *Department of Clinical Laboratory, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Weichun XiaoThe Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Jiale KangDepartment of Clinical Laboratory, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Qiang ZhouDepartment of Clinical Laboratory, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China.
Hongyun JiaDepartment of Clinical Laboratory, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China. 2010682001@gzhmu.edu.cn.
Yimei ChenPhysical Examination Center, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China. 2017682034@gzhmu.edu.cn.
Sicong HuangDepartment of Clinical Laboratory, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China. 2018682005@gzhmu.edu.cn.

Funding

Guangdong Medical Science and Technology Research Fund Project A2023165Guangdong Medical Science and Technology Research Fund Project B2023049Guangzhou Health Science and Technology Project 20251A011073Guangzhou Health Science and Technology Project 20251A011074
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is frequently associated with Yeats-domain containing 2 (YEATS2) overexpression, which enhances tumor progression via the PI3K/AKT pathway. Our study delineates YEATS2's oncogenic functions in HCC and its potential as a prognostic and predictive biomarker. Through comprehensive in vitro and bioinformatics analyses, we reveal that YEATS2 promotes cell proliferation, invasion, and epithelial-mesenchymal transition (EMT). Additionally, YEATS2 modulates the tumor immune microenvironment and predicts response to immunotherapies and chemotherapies. YEATS2's serum stability suggests its utility as a non-invasive biomarker for personalized HCC treatment.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAcetylationAnimalsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansPrognosisTumor MicroenvironmentBiomarkers, TumorHepatocellular carcinomaOncogenesisTreatment strategiesYEATS2

Identifiers

PMID40731114
PMCPMC12307690

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.